About half of all melanomas have mutations in the BRAF gene that accelerate tumor cell growth and spread. While most patients benefit from targeted anti-BRAF therapy, resistance to treatment and tumor progression is almost inevitable.
Vito Quaranta, MD, and colleagues studied the response of several BRAF-mutated melanoma cell lines to BRAF inhibitors. Reporting March 27 in the Biophysical Journal, they found that treated cells entered a previously unrecognized "idling" state in which the number of dividing cells matched the number of dying cells.
They developed a mathematical model of drug-response dynamics to explain how treatment may alter the "epigenetic landscape" melanoma cells inhabit leading to a state of zero net growth. They speculate that idling cancer populations, primed to acquire resistance mutations, may constitute the bulk of residual disease.
More information: B. Bishal Paudel et al. A Nonquiescent "Idling" Population State in Drug-Treated, BRAF -Mutated Melanoma, Biophysical Journal (2018). DOI: 10.1016/j.bpj.2018.01.016
Journal information: Biophysical Journal
Provided by Vanderbilt University